Compare Davita Inc (DVA) vs Lam Research Corporation (LRCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Lam Research Corporation — how do they compare? Davita Inc trades at $178.61 (market cap $11.38B), while Lam Research Corporation trades at $327.69 (market cap $389.67B). The key difference: Lam Research Corporation is far larger — about 34.2× Davita Inc's market cap, and Lam Research Corporation pays a 0.33% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | LRCX | |
|---|---|---|
Market Cap | $11.38B | $389.67B |
Sector | Health | Technology |
52-Week High | $240.96 | $433.33 |
52-Week Low | $103.87 | $97.03 |
Enterprise Value | $24.10B | $387.83B |
Dividend Yield | — | 0.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
Lam Research (LRCX) trades at $306.4, down 1.59% on the day, with a neutral technical signal. The company shows strong fundamentals, including a 31.27% net income margin and three consecutive quarterly EPS beats. Recent news highlights expansion into panel-level packaging and workforce development collaborations, supporting growth in the AI-driven semiconductor equipment sector.
Outlook remains positive with a consensus price target of $397.18, implying significant upside. Risks include competitive pressures from new entrants like SpaceX's Terafab and reliance on AI chip demand cycles. Analyst sentiment is strongly bullish with 78% buy ratings, but investors should monitor execution against high valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
